SpIntellx
Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center, as well as external collaborators from academia, federal agencies and industry.
Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.
This person is not in the org chart
This person is not in any offices
SpIntellx
SpIntellx harnesses the computational power of proprietary unbiased spatial analytics, spatial systems pathology, and explainable artificial intelligence (xAI) to extract information from patient primary disease pathology samples to create predictive knowledge that is required to develop personalized therapeutic strategies, identify potential novel targets for drug discovery, optimally select patient cohorts for clinical trials and improve the predictive power of prognostics/diagnostics.